Bucillamine is an orally active immunomodulator useful in the treatment of rheumatoid
arthritis. Its potencies in inhibiting collagenase activity and inactivating rheumatoid factor
far exceed those of penicillamine. In man, bucillamine reportedly brings about significant
improvements over placebo in erythrocyte sedimentation, grip power, joint swelling and
duration of morning stiffness.